Drugs / EBV-AST cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07438067 | Mar 2025 → Mar 2028 expected | Epstein-Barr virus infection, post-transplant lymphoproliferative disease | Daihong Liu | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-AST cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07438067 ↗ |
| Known as | EBV-AST | “EBV-AST (EBV-specific cell infusion) for the treatment of EBV-DNA viremia and prevention of PTLD in patients post-Allo-HSCT.” NCT07438067 ↗ |
| Modality | Cell therapy | “EBV-AST (EBV-specific cell infusion)” NCT07438067 ↗ |